Corvus Pharmaceuticals (NASDAQ:CRVS) Stock Price Down 8.6% – Time to Sell?

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS)’s stock price was down 8.6% on Tuesday . The stock traded as low as $8.73 and last traded at $8.74. Approximately 493,465 shares traded hands during trading, an increase of 40% from the average daily volume of 353,164 shares. The stock had previously closed at $9.56.

Analyst Upgrades and Downgrades

CRVS has been the subject of several recent analyst reports. Mizuho upgraded Corvus Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Tuesday, October 22nd. LADENBURG THALM/SH SH boosted their price objective on shares of Corvus Pharmaceuticals from $12.00 to $21.00 and gave the company a “buy” rating in a research report on Monday, September 16th. Finally, StockNews.com lowered Corvus Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, October 31st. One equities research analyst has rated the stock with a sell rating, three have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $10.83.

Corvus Pharmaceuticals Trading Down 9.1 %

The stock has a market capitalization of $543.56 million, a P/E ratio of -20.04 and a beta of 1.05. The business has a 50-day moving average price of $6.47 and a two-hundred day moving average price of $3.88.

Institutional Trading of Corvus Pharmaceuticals

A number of hedge funds have recently bought and sold shares of CRVS. Cubist Systematic Strategies LLC bought a new stake in shares of Corvus Pharmaceuticals during the second quarter valued at approximately $44,000. Nwam LLC purchased a new stake in Corvus Pharmaceuticals during the 3rd quarter valued at $53,000. Oppenheimer & Co. Inc. purchased a new stake in shares of Corvus Pharmaceuticals in the third quarter worth approximately $89,000. Marshall Wace LLP bought a new stake in shares of Corvus Pharmaceuticals during the second quarter valued at approximately $136,000. Finally, Avity Investment Management Inc. increased its position in Corvus Pharmaceuticals by 138.2% during the 3rd quarter. Avity Investment Management Inc. now owns 27,580 shares of the company’s stock valued at $146,000 after purchasing an additional 16,000 shares during the period. Institutional investors own 46.64% of the company’s stock.

About Corvus Pharmaceuticals

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.